General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


Effects of Combined Insulin-like Growth Factor 1 and Macrophage Colony-stimulating Factor on the Skeletal Properties of Mice. S.A. LLOYD, S.J. SIMSKE, L.K. BOGREN, S.E. OLESIAK, T.A. BATEMAN, V.L. FERGUSON (Hershey, PA; Boulder; Fort Collins, CO; Chapel Hill, NC, USA)

Cell Death Detection after High-LET Irradiation in an Orthotopic Human Hepatocellular Carcinoma in Vivo. A. ALTMEYER, M. IGNAT, J.-M. DENIS, N. MESSADDEQ, J. GUEULETTE, D. MUTTER, P. BISCHOFF (Strasbourg, Illkirch Graffenstaden, France; Brussels, Belgium)

Serum Calcium-decreasing Factor, Caldecrin, Ameliorates Muscular Dystrophy in dy/dy Mice. M. TOMOMURA, T. FUJII, H. SAKAGAMI, A. TOMOMURA (Saitama; Tokushima, Japan)

Nitric Oxide Concentrations are Normal and Unrelated to Activity Level in Chronic Fatigue Syndrome. M. MEEUS, I. VAN EUPEN, J. HONDEQUIN, L. DE HAUWERE, D. KOS, J. NIJS (Antwerpen; Brussel, Belgium)

Gene Expression Analysis of Oxidative Stress and Apoptosis in Proton-irradiated Rat Retina. X.W. MAO, L.M. GREEN, T. MEKONNEN, N. LINDSEY, D.S. GRIDLEY (Loma Linda, CA, USA)

Colon Cancer Vaccines: An Update. E. MERIKA, M.W. SAIF, A. KATZ, K. SYRIGOS, M. MORSE (London, UK; Haven, CT; Durham, NC, USA; Athens, Greece)


CD95 and TNFα-induced Apoptosis in Liver Metastases of Colorectal Carcinoma. H.-U. KASPER, E. KONZE, M. KERN, D.L. STIPPEL (Münster; Köln; Heidelberg, Germany)

Thrombogenicity of Sirolimus-eluting Stents and Bare Metal Stents: Evaluation in the Early Phase after Stent Implantation. T. WALTER, K.S. REY, H.P. WENDEL, S. SZABO, T. SUSELBECK, C.-E. DEMPFLLE, M. BORGREFFE, S. SWOBODA, M.E. BEYER, H.M. HOFFMEISTER (Mannheim;_RTCheim; Tuebingen; Solingen, Germany)

Non-antibiotics Reverse Resistance of Bacteria to Antibiotics. J.E. KRISTIANSEN, V.F. THOMSEN, A. MARTINS, M. VIVEiros, L. AMARAL (Odense; Copenhagen, Denmark; Lisbon, Portugal)


A Possible Mechanism for Altered Immune Response in the Elderly. G. MAZZOCCOLI, A. DE CATA, S. CARUGHI, A. GRECO, M. INGLESE, F. PERFETTO, R. TARQUINI (San Giovanni Rotondo; Florence, Italy)

Urine and Serum Analysis of Consumed Curcuminoids Using an IκB-luciferase Surrogate Marker Assay. S. PONNURANGAM, F.G. MONDALEK, J. GOVIND, D. SUBRAMANIAM, C. HOUCHEN, S. ANANT, P. PANTAZIS, R.P. RAMANUJAM (Oklahoma City, OK, USA)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Phase II Study of Weekly Paclitaxel and Doxifluridine Combination Chemotherapy for Advanced/Recurrent Gastric Cancer. I. TAKEYOSHI, F. MAKITA, Y. TANAHASHI, S. IWAZAKI, T. OGAWA, N. TOMIZAWA, S. NAKAMURA, H. ISHIKAWA, T. OHYA, S. KAKINUMA, K. NAKAGAMI, Y. SATO, T. KOYANO, T. ROPPONGI, M. IWUMI, J. KOBAYASHI, S. KAWATE, Y. SUNOSE, M. KOBAYASHI, T. YAMADA, I. SAKAMOTO (Maebashi; Shibukawa; Tatebayashi; Takasaki; Ota; Numata; Annaka, Gunma; Yamanashi, Yamanashi; Ojiya, Nippon; Shimada, Shizuoka; Saitama, Saitama, Japan) ........................................ 287

Cortactin in Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, C.-Y. HUANG, Y.-Y. LIU, C.-C. HUANG, R.-P. TANG (Kaohsiung, Taiwan, ROC; Xiamen, PR China) ....................... 293

Successful S-1 Monotherapy for Chemorefractory Thymic Carcinoma. T. KOIZUMI, T. AGATSUMA, Y. KOMATSU, K. KUBO (Matsumoto, Nagano, Japan) .................................................. 299

Prognostic Value of the Human Antigen R (HuR) in Human Breast Cancer: High Level Predicts a Favourable Prognosis. Z. YUAN, A.J. SANDERS, LI. YE, Y. WANG, W.G. JIANG (Cardiff, UK; Beijing, PR China) .......... 303

Pronounced Tumour Regression after Radiotherapy is Associated with Negative/Weak Glucose Transporter-1 Expression in Rectal Cancer. E. KORKEILA, P.M. JAAKKOLA, K. SYRJÄNEN, S. PYRHÖNEN, J. SUNDSTRÖM (Turku, Finland) ............................................................................................................. 311

Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer. K. JAHNKE, U. KEILHOLZ, D. LÜFTNER, E. THIEL, A. SCHMITTEL (Berlin, Germany) .... 317

Clinical Significance of STC1 Gene Expression in Patients with Colorectal Cancer. S. TAMURA, T. OSHIMA, K. YOSHIHARA, A. KANAZAWA, T. YAMADA, D. INAGAKI, T. SATO, N. YAMAMOTO, M. SHIOZAWA, S. MORINAGA, M. AKAIKE, C. KUNISAKI, K. TANAKA, M. MASUDA, T. IMADA (Takagawa-ken, Japan) .... 325

Temsirolimus in Metastatic Chromophobe Renal Cell Carcinoma after Interferon and Sorafenib Therapy. B. PAULE, N. BRION (Creteil; Le Chesnay; Guyancourt, France) .................................................. 331

5-FU-induced Hyperammonemic Encephalopathy in a Case of Metastatic Rectal Adenocarcinoid Successfully Rechallenged with the Fluoropyrimidine Analog, Capecitabine. P.P. ADVANI, M.G. FAKIH (Buffalo, NY, USA) ... 335


The Dynamics of Serum Tumor Markers in Predicting Metastatic Uveal Melanoma (Part 1). V. BARAK, I. KAISERMAN, S. FRENKEL, K. HENDLER, I. KALICKMAN, J. PE’ER (Ashkelon; Jerusalem, Israel) ...... 345


Risk of Ipsilateral Breast Tumor Recurrence in Patients Treated with Tamoxifen or Anastrozole Following Breast-conserving Surgery with or without Radiotherapy. M. ISHITOBI, S. NAKAHARA, Y. KOMOIKE, K. MOTOMURA, H. KOYAMA, H. INAJI (Osaka, Japan) .................................................. 367

Parameters of Biological Activity in Colorectal Cancer. S. SVOBODOVA, O. TOPOLCAN, L. HOLUBEC Jr., M. LEVY, L. PECEN, S. SVACINA (Prague, Czech Republic) ........................................ 373

* Review (page 271)
Oleic Acid Is the Active Component in the Mushroom *Daedalea gibbosa* Inhibiting Bcr-Abl Kinase Autophosphorylation Activity. H. KHAMAISIE, S. SUSSAN, M. TAL, Y. NAJAREH, M. RUTHARDT, J. MAHAINA (Kiryat Shmona; Ness-Ziona, Israel; Jerusalem-Abu Dies, Palestine; Frankfurt, Germany) .

Chemical Composition and Antiproliferative Activity of Essential Oil from the Leaves of a Medicinal Herb, *Levisticum officinale*, against UM-SCC1 Head and Neck Squamous Carcinoma Cells. S. SERTEL, T. EICHHORN, P.K. PLINKERT, T. EFFERTH (Heidelberg; Mainz, Germany) ........................................

Anticancer and Antimetastatic Activities of Renieramycin M, a Marine Tetrahydroisoquinoline Alkaloid, in Human Non-small Cell Lung Cancer Cells. H. HALIM, P. CHUNHACHA, K. SUWANBORIRUX, P. CHANVORACHOTE (Bangkok, Thailand) .................................................................

ATM/ATR and SMAD3 Pathways Contribute to 3-Indole-induced G1 Arrest in Cancer Cells and Xenograft Models. S.-M. HUANG, K.-T. LU, Y.-C. WANG (Taipei; Tainan, Taiwan, ROC) ........................................

Effect of Genistein on p90RSK Phosphorylation and Cell Proliferation in T47D Breast Cancer Cells. J. GWIN, N. DREWS, S. ALI, J. STAMSCHROR, M. SORSENSON, T.T. RAJAH (Chicago, IL, USA) ....................................

Increased Efficacy and Reduced Cardiotoxicity of Metronomic Treatment with Cyclophosphamide in Rat Breast Cancer. V.K. TODOROVA, Y. KAUFMANN, V.S. KLIMBERG (Little Rock, AR, USA) ..........


*Ruta graveolens* Extract Induces DNA Damage Pathways and Blocks Akt Activation to Inhibit Cancer Cell Proliferation and Survival. K. FADLALLA, A. WATSON, T. YEHUALAESLET, T. TURNER, T. SAMUEL (Tuskegee, AL, USA) .

Clinical Studies

Detection and Significance of Parametrial Micrometastases in Early-stage Cervical Cancer. P.C. BRADY, X. CHEN, W.M. BURKE, I. DEUTSCH, X. SUN, T.J. HERZOG, J.D. WRIGHT (New York, NY, USA) ............

Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). M.G. FURY, S. BAXI, R. SHEN, K.W. KELLY, B.L. LIPSON, D. CARLSON, H. STAMBUK, S. HAQUE, D.G. PFISTER (New York, NY, USA) ............


Expression of LGR5, an Intestinal Stem Cell Marker, During Each Stage of Colorectal Tumorigenesis. K. TAKEDA, I. KINOSHITA, Y. SHIMIZU, Y. MATSUNO, T. SHICHINOHE, H. DOSAKA-AKITA (Sapporo, Japan) .......... 

* Short Review: The Role of Pelvic Lymph Node Dissection During Radical Cystectomy for Bladder Cancer. E. BRUNOCILLA, R. PERNETTI, G. MARTORANA (Bologna, Italy).................................

Two Cases with a Long-term Survival Following Multidisciplinary Treatment for Recurrent Breast Cancer After Surgery. H. URAMOTO, T. HANAGIRI (Kitakyushu, Japan) ........................................

C-erbB-3 Expression in Non-small Cell Lung Cancer (NSCLC) Patients Treated by Erlotinib. I. CsTOTH, G. ANTHOINE, T. BERGHMANS, C. MASCAUX, M. PAESMANS, J.-P. SCULIER, A.-P. MEERT (Brussels, Belgium) ..........................................................
EGFR Codon 497 Polymorphism – Implications for Receptor Sensitivity to Inhibitors in HNSCC Cell Lines. V. KROHN, S. WIEGAND, J.A. WERNER, R. MANDIC (Marburg, Germany) ................................................................. 59


TIP60 as a Potential Marker for the Malignancy of Gastric Cancer. K. SAKURABA, K. YOKOMIZO, A. SHIRAHATA, T. GOTO, M. SAIITO, K. ISHBASHI, G. KIGAWA, H. NEMOTO, K. HIBI (Yokohama, Japan) ........................................................................................................................................................................ 77

Cytotoxicity of Thymus vulgaris Essential Oil Towards Human Oral Cavity Squamous Cell Carcinoma. S. SERTEL, T. EICHHORN, P.K. PLINKERT, T. EFFERTH (Heidelberg; Mainz, Germany) ................................................................. 81

Thyroid Hormones (T3 and T4): Dual Effect on Human Cancer Cell Proliferation. G. MORIGGI, C. VERGA FALZACAPPA, C. MANGIALARDO, S. MICHENZI, A. STIGLIANO, E. BRUNETTI, V. TOSCANO, S. MISITI (Rome, Italy) ........................................................................................................................................................................ 89


NK4 Gene Therapy Combined with Cisplatin Inhibits Tumour Growth and Metastasis of Squamous Cell Carcinoma. G. MATSUMOTO, Y. OMI, U. LEE, E. KUBOTA, Y. TABATA (Kanagawa; Kyoto, Japan) ........................................................................................................................................................................ 105

Constitutively Active FGFR3 with Lys650Glu Mutation Enhances Bortezomib Sensitivity in Plasma Cell Malignancy. M. OTSUKA, M. MIZUKI, J. FUJITA, S. KANG, Y. KANAKURA (Osaka, Japan; Atlanta, GA, USA) ........................................................................................................................................................................ 113

The Tumor Suppressive Effect of Angiotensin II Type 1 Receptor Antagonist in a Murine Osteosarcoma Model. J. WASA, H. SUGIURA, E. KOZAYAMA, K. YAMADA, O. TAGUCHI (Nagoya, Japan) ........................................................................................................................................................................ 123


Oncogramme, A New Promising Method for Individualized Breast Tumour Response Testing for Cancer Treatment. S. GIRAUD, E. LOUM, B. BESSETTE, V. FERMEAUX, C. LAUTRETTE (Limoges Cedex, France) ........................................................................................................................................................................ 139

Hepatic Arterial Infusion in the Treatment of Liver Metastases with PEG Liposomes in Combination with Degradable Starch Microspheres (DSM) Increases Tumor 5-FU Concentration. An Animal Study in CC-531 Liver Tumor-bearing Rats. U. POHLEN, R. RESZKA, H.J. BUHR, G. BERGER (Berlin, Germany) ........................................................................................................................................................................ 147

Improvement of Biodistribution with PEGylated Liposomes Containing Docetaxel with Degradable Starch Microspheres for Hepatic Arterial Infusion in the Treatment of Liver Metastases: A Study in CC-531 Liver Tumor-bearing WAG RII Rats. U. POHLEN, H.J. BUHR, G. BERGER (Berlin, Germany) ........................................................................................................................................................................ 153

Neem Leaf Extract Induces Radiosensitization in Human Neuroblastoma Xenograft Through Modulation of Apoptotic Pathway. J. VEERARAGHAVAN, S. ARAVINDAN, M. NATARAJAN, V. AWASTHI, T.S. HERMAN, N. ARAVINDAN (Oklahoma City, OK; San Antonio, TX, USA) ........................................................................................................................................................................ 161

MAGE Expressions Mediated by Demethylation of MAGE Promoters Induce Progression of Non-small Cell Lung Cancer. N. YANAGAWA, G. TAMURA, H. OIZUMI, M. ENDOH, T. MOTOYAMA (Yamagata, Japan) ........................................................................................................................................................................ 171

Contents continued on the preceding page